igy_presentation jan 2010 nml wpg

8/14/2019 Igy_presentation Jan 2010 NML WPG

1/52

BEYOND ANTIBIOTICS -TREATING VIRUSES & BACTERIA PATHOGENS WITH

SPECIFIC ANTIBIODIES - AND ELIMINATING THE SIDE

EFFECTS IN THE PROCESS.

JANUARY 26TH - NATIONAL MICROBIOLOGY LABORATORY


2/52

IGY Immune Technologies & Life Sciences Inc.

SAFE HARBOUR STATEMENTS

The information in this presentation is being made available to you and a limited number of other prospective investors on a confidential

basis, solely for the purpose of your consideration of an investment in securities under a securities purchase agreement, and such

information may not be used for any other purpose.

The information contained herein has been obtained from IGY Immune Technologies and Life Sciences Inc. (the Company) and from

sources believed by the Company to be reliable. The Company makes no representations or warranties, express or implied, as to the

accuracy or completeness of this information. The Company expressly disclaims any and all liability from any untrue statements or

omissions, which may be contained in this presentation or any other written or oral communication transmitted or made available to a

prospective investor. Only those particular representations made in a securities purchase agreement shall have any legal effect.

Certain statements in this presentation, such as those concerning the Companys business strategy, products, revenues and capital

requirements, and other statements regarding matters that are not historical facts, and the Companys financial projections included herein,

are forward-looking statements (as defined in the securities act of 1933). Because such forward-looking statements include

risk and uncertainties, actual results may differ materially from those expressed in or implied by such forward-looking statements.

During the course of your evaluation, all inquiries and other communications are to be made only to employees or representatives of the

Company. Accordingly, you agree not to directly or indirectly discuss with, or offer to, any third party a participation in a possible transaction

or any other form of joint investment or acquisitionby you and such third party without The Companys prior written consent.


3/52


PRESENTATION OVERVIEW

Overview

What We Do

Our Mission

The Trillion Dollar Health and Wellness Market

Building Immune Systems and Treating Specific World Health Problems

The Technology

Market Segments:

Medicines

Functional Foods

Agribusiness & Packaged Consumer Meat Producers

Cosmeceuticals

Corporate Structure

Strategic Timeline

Leverage Through Partnerships

Financial Forecasts

Financing Objectives

Management Team, Consultants, Advisory Board, Board Of Directors


4/52


WHAT WE DO

IGY Immune Technologies and Life Sciences specializes in the extraction of

polyclonal immunoglobulin antibodies, a type of antibodies that are derived fromchicken eggs for use as a nutraceutical for human consumption.

Immunoglobulins are powerful antibodies produced in healthy humans and other

animals to fight infections and prevent disease. Egg yolks contain immunoglobulin

IgY, the functional equivalent of immunoglobulin IgG which makes up 75% of the

immunoglobulin found in healthy human plasma.

Our proprietary technology and processes makes it possibleto create health products to strengthen and supplement yournatural immune system against certain types of bacteriaviruses and other autoimmune ailments.


5/52


OUR MISSION

IgY Immune Technologies and Life Sciences Inc. is in the business of designing specific antibodies through natural

sources and purifying them through its proprietary extraction methods. By introducing specific antibodies to theanimal kingdom, we have the ability to prevent disease, save lives and reduce our dependence on antibiotics.

By improving the bodys natural immune system, like never before, we can improve the lives of millions suffering

from viral, bacterial, and autoimmune diseases.

By preventing the spread of disease, we can save hundreds of billions in valuable tax resources; allowing

governments to redirect their resources into other areas of science, to lower the costs of healthcare systems

around the world and ultimately, bring IgY medicine to the developing world.

By arming veterinary science with improved methods to farm our agriculture and aquaculture industries, we will

create a stronger food network and at the same time, a safer drinking water system by reducing its over use of

antibiotic drugs.

By extending these same specific antibodies to our family pets, they can live longer, healthier lives for everyone

to enjoy.

By putting into effect the knowledge of immunologists and microbiologists around the world, our scope of

science to be discovered is incredible.

By achieving all of this, our stakeholders will be pioneers in medical science and earn a valuable share in our

financial successes.

The Cure is in the Prevention. IgY for Life.


6/52


THE TRILLION DOLLAR HEALTH & WELLNESS MARKET

THE MARKET OPPORTUNITY

Public health awareness continues to shift towards disease prevention

Boosting immune systems will become an increasingly important focus

Dietary supplements and vitamins, already used extensively, don't contain the

antibodies needed to fight off or prevent disease


7/52


THE TRILLION DOLLAR HEALTH & WELLNESS MARKET


8/52


Alexander FlemingDiscovered Penicillin, 1928

80 YEARS OF ANTIBIOTICS

BUILDING THE IMMUNE SYSTEM AND TREATING WORLD HEALTH PROBLEMS

In his 1945 Nobel Prize address,

Alexander Fleming warned that it

was easy to produce microbes

resistant to his discovery, penicillin.

Simply expose them to concentrations

of the drug was insufficient to killthem.

John Hopkins Magazine, John Hopkins University


9/52



Viral Bacteria

Autoimmune


10/52




11/52



June 24, 2009


12/52



August 3, 2009


13/52



I suffer no illusions that this will be an

easy process. It will be hard. But I also

know that nearly a century after Teddy

Roosevelt first called for reform, the cost of

our health care has weighed down our

economy and the conscience of our nation

long enough. So let there be no doubt;health care reform cannot wait, it must

not wait, and it will not wait another year.

- President Barack Obama, February 2009.

Under the proposed Preservation of Antibiotics for Medical Treatment Act, or PAMTA, newly-developedantibiotics couldnt be given to farm animals unless they were sick. The casual use of already-establisheddrugs would be restricted.

- Brandon Keim, Wired Magazine, July 21, 2009


14/52



Focusing in the immune system isa natural evolution in fight againstdiseases. Medical science isrecognizing the importance of

strengthening innate immunesystem and reducing reliance onantibiotics.


15/52


THE TECHNOLOGY

Breakthrough

IRIs ground-breaking technology opens

the wide doorway to a whole new

science.


16/52


Viral infections include:

All colds and flu

Most coughs Most sore throats, and

Usually involve several

parts of the body

THE TECHNOLOGY

IgY Works on Both Viral and Bacteria Infections

Bacterial infections include:

Strep throat

Urinary tract infections Most ear infections

Some sinus infections, and

Are usually localized at a

single point in the body


17/52


18/52


ANTIBODY YIELD FROM HENS

THE TECHNOLOGY

A laying hen can produce approximately 300 eggs annually and the volume

of one egg yolk is approximately 15 ml.

This could supply close to 100g of antibody per hen per year.

Each Eggs contain approximately 3-5mg IgY per ml of yolk (70-100mg of

total IgY antibody depending upon the size of the egg)

Of this total and depending on the concentration level required for

commercial effectiveness, our technology can generate as little as10% or as

much as 75% antibody against a specific antigen.


19/52


ADVANTAGES OF ANTIBODIES FROM EGG YOLKS OVER MAMMALIAN ANTIBODIES

THE TECHNOLOGY

a. A single egg contains as much antibody as an average bleed from a rabbit. In addition,

egg collection is simple and noninvasive. Eggs are generally laid on a daily basis,

whereas a rabbit may only be bled once every 2-3 weeks.

b. Chickens require only a one month immunization regimen to obtain high titers of

polyclonal antibody. To ensure a rabbit is producing high titers of antibody, the

immunization procedure requires up to 2-3 months.

c. Similar amounts of antigen are required to immunize chickens and rabbits, but daily egg

collection occurs over a month and titers generally remain high during this period. A

rabbit may be bled only once every 2-3 weeks and the amount of antibody contained in

the sera is equivalent to the amount of antibody in a single egg.

d. Because the phylogenetic distance between birds and mammals is great, chickens are

very useful for producing antibodies against conserved mammalian proteins. Typically, 1-

5% of rabbit sera will be comprised of antibodies against a specific mammalian antigen.

About 2-10% of a chicken egg yolk is comprised of antigen-specific antibodies. In

addition, very highly conserved mammalian proteins sometimes fail to elicit an immune

response in rabbits but antibodies against these proteins are often successfully produced

in the avian system.


20/52


THE PROCESS OF MAKING IGY ON A COMMERCIAL SCALE

160,000

eggs per

day.

ONE

KILO of

50%

Pure IgY

350

birds =10,500

eggs


21/52



Eggs arebroken at aCFIA eggstation


22/52



then mixed

with water andcentrifuged tocreate a Water

SolubleFraction,containing thedesired IgY.


23/52



The prototypefacility was over$10 million indesign andinstallation.Capable ofproducing up to2,000 kg permonth of IgY.


24/52


ISOLATION OF IGY FROM EGG YOLKResults: SDS-PAGE

IgY

Rm rt+w1 w2 el


25/52


App. 60 % purity

IgYResults: Size exclusion chromatography

ISOLATION OF IGY FROM EGG YOLK


26/52


EFFECTIVENESS OF IGY FOR SALMONELLA

THE TECHNOLOGY


27/52


COMPETITIVE ADVANTAGES

THE TECHNOLOGY

Higher concentration of IgY (traditional 5% purity vs. 25% or >)

Fats are removed

No Cholesterol

Pharmaceutical grade

Tasteless and odorless

Can be designed for a variety of applications

Can be used in an aerosol

No competitive technology

Comprehensive patents on intellectual property

.


28/52


INTELLECTUAL PROPERTY PROTECTION

THE TECHNOLOGY

Our Companys value lies in our ability

to continuously generate new IP

protection for IgY. We are regularly

adding new patents to our existing

portfolio.

Patent approvals are sought

internationally for ingredients and

processes and for products that are

developed.

We have chosen not patent certain key

elements of our process for addedprotection.


29/52


MANUFACTURING & PRODUCTION

THE TECHNOLOGY

Control over egg supply chain

Eggs are the most economical and practical solution as chickens lay eggs

regularly, so there is a continual source of antibody Agreements secured with suppliers

economical and practical solution deal to the leftover egg byproduct

.


30/52


MARKET SEGMENTS

COMMERCIAL APPLICATIONSOur commercial applications fall across 4 primary sectors which means we can grow

our product base and revenue streams against any cyclical variations.


31/52


MARKET SEGMENTS: MEDICINES

IGY SPECIFIC - CLOSTRIDIUM DIFFICILE (C.DIFFICLE)

Ig(Y) specific for Clostridium Difficile Bacteria.

Under development with Dr. Michelle Alfa, University of

Manitoba and St. Boniface Hospital

Expected combined phase I and II trials to be completed

within 24 months, and a marketable pharmaceutical ready

for 2012

Expected to generate over a Billion dollars of revenue in

North America alone.

Dr. Alfa has already proven the viability of generating theantigens from the eggs, the problem remained commercial

ability to produce an Ig(Y) Specific, which has now been

solved.


32/52


Potentially lethal cases ofC. Difficile rocketed from 1990s to 2004

Cases had increased from 1,000 in 1990 to over 35,000 in 2003

44,488 cases ofC. Difficile in > 65 year olds in 2004.

Good new stats here on C. Dif. with 7,000 cases per day, and 300

mortalities per day.

$51.5 million in health care costs, per day in the United States. That is

$18.8 Billion per year in costs. This just for C. Diff. not to mention MSRA.

A single occurrence of CDI adds about $3,700 to a hospital bill and can

mean three or more additional nights in the hospital.

BBC News. http://news.bbc.co.uk/2/hi/health/4186834.stm

LETHAL HOSPITAL BUG CASES ROCKET, UNITED KINGDOM

MARKET SEGMENTS: MEDICINES

CLOSTRIDIUM DIFFICILE (C.DIFFICLE)


33/52


MARKET SEGMENTS: FUNCTIONAL FOODS


34/52



Multi-Million dollar letter of intent signed December 25th,

2008.

Pharma Foods markets a variety of Ig(Y) products.

Majority of Asians and Mexicans suffer from HP bacteria.

Second part of agreement to produce H5N1 (avian flu)

antibody.

Current processes provide approximately 5% purity of H. Pylori

IGY. Our process provides 50-75% purity of H. Pylori IGY.

PHARMA FOODS INTERNATIONAL CO., LTD

Discussions with Pharma Company in China to produce a H.Pylori

pharmaceutical.
http://images.google.ca/imgres?imgurl=http://web.1.c2.audiovideoweb.com/1c2web3536/IgYYogurtinJAPAN%20-%20Credit%20-%20Pharma%20Food%20International%20Co.,%20Ltd..jpg&imgrefurl=http://portal.acs.org/portal/PublicWebSite/pressroom/newsreleases/WPCP_012358&usg=__k9y4wb1uZIurOwmxeSrKkvD728c=&h=2448&w=3264&sz=1769&hl=en&start=2&sig2=lbF3YDuwfTmWAogDhdOKLA&tbnid=fiucbdmfI-4ZNM:&tbnh=113&tbnw=150&prev=/images?q=gut+yogurt+korea&hl=en&rlz=1T4ADBF_enCA317CA318&ei=nMtnSs_iLozflAfRgrDECQ


35/52



http://www.pharmafoods.co.jp


36/52


MARKET SEGMENTS: AGRIBUSINESS AND PACKAGED CONSUMER MEATS


37/52


MARKET SEGMENTS: COSMECEUTICALS

The cosmeceuticals market is forecasted to reach $21 billon by 2012

Sales of natural body care products are thriving with 14% growth in 2007

and annual compound growth of 57% since 2004

Skin care, hair care and colour cosmetic cosmeceuticals showed an overall25% gain in the retail sector between 2003 and 2007

THE COSMECEUTICALS MARKET


38/52



Our Acne Product is an antibody tailored skin treatment. The antibody is made in a similar way to

that of making a vaccine. The antibody is a specific immunoglobulin (IgY) that we produce targets

for Propionibacterium Acnes or P. Acnes for short. The exact cause for all forms of acne (pimples,

whiteheads, blackheads, mild and severe lesions) is not known but researchers believe there are

many related factors. However, common to all forms of acne is the culprit, P. Acnes. Our acnetreatment inactivates P. Acnes and thereby removes the major cause of skin inflammation and

disease. Without P. Acnes the skin will heal and new lesions will not occur.

BeforeTreatment

AfterTreatment

A natural and a safe alternate to AntibioticTreatment for Acne


39/52



1. Cleansing Mousse : Contains Natural Oceanic Clay, Herbs and Vitamin E to protect and

maintain the skins health while natural emulsifiers and scrubbing beads remove makeup

and soils effectively.

2. Natural Oceanic Clay mask with IgY: Anti-Acne Clay Mask with IgY helps combat

blemishes and blackheads in a double action through the combined forces of our Natural

Oceanic Clay and APA - IgY.

3. Moisturizing Cream with IgY: This anti-acne moisturizing cream is formulated as a

treatment for prevention of acne skin infections caused by Propionibacterium acne. Our

unique antibody treatment APA-IgY (Anti Propionibacterium Acnes-IgY) penetrates theskin and destroys the Propionibacterium Acne-bacteria that is common among all forms of

acne, and prevents the appearing of blackheads and blemishes. Panthenol and Sunflower

Oil moisturizes the skin. This beneficial formula completes the treatment of acne while

maintaining the healthy condition of the skin.

The IGY Skincare Program is a completesystem of three products


40/52



"Proactiv has become a phenomenon by transformingthe way consumers think about pimples. The brand

captured public attention by hiring stars for its

infomercials like Vanessa Williams, Jessica Simpson

and Sean Combs to lay bare their valiant struggles to

attain flawless skin, effectively turning acne into a

celebrity malady. But the companys real innovation

was repositioning mild breakouts from a routine

annoyance that a dab of Clearasil might fix to a

preventable condition, like cavities, requiring vigilant

daily upkeep.

The brand now has more thanfive million active

customers and annual worldwide sales of about $850

million, 70 percent of which are in the United States.

Right now, we own acne, said Greg Renker, a chief

executive of Guthy-Renker, the direct-response

television company that sells Proactiv

New York Times, October 2007

INFOMERCIAL STRATEGY
http://flaggedforfollowup.typepad.com/.shared/image.html?/photos/uncategorized/2007/10/18/proactive_jessica_simpson.jpg


41/52


STRATEGIC TIMELINE


42/52


GloBayne Marketing

International

FedNor

Maple Leaf Foods Provincial Health Care

Ministries

National Research

Counsel, IRAP program Ironwood Clay Company

LEVERAGE RESOURCES THROUGH PARTNERSHIPS


43/52


THE OPPORTUNITY LIES IN OUR LEADERSHIP

While the current budget is set for cosmeceutical and

nutraceutical applications, the opportunity for the National

Microbiology Lab lies in a joint effort to create the first

pharmaceutical IgY product.

A C. Difficile IgY Specific remains our top priority. Much of the phase I & II clinical work has been completed

by the SBRC.

Steps to move forward include acquiring a government

approved vaccine for C. Difficile, producing a test sample of

IgY Specific C. Difficile, completing the requirements forhuman testing.


44/52


ELISAC.difficile

00.10.20.30.40.50.60.70.8

62.5 125 250 500 1000 2000 4000 8000[IgY] (ng/mL)

A(4

05

nm

)SigmaIRI 27067IRI 07067IRI 27067 Eggcellent Extractblank (diluent)3% gelatin coated vs 27067 extract3% gelatin coated vs 27067

THE OPPORTUNITY LIES IN OUR LEADERSHIP


45/52


IGY C. DIFFICILE SPECIFIC SAVE LIVES & MONEY

Currently, 300 people per day die as a result of C. Difficile

related causes in the USA everyday.

The cost to the US health-care system is $51.5 million per

day.

The average cost of a stay in a Canadian hospital is $1,350,

escalating to $2,500 per day in an isolation room.

We estimate that at 75% of the patient load in a health

care facility taking C. difficile IgY Specific antibodies, at

$3.50 per day would save roughly $16 billion in health carecosts in North America and 120,000 lives annually.


46/52


IMAGINE THE POSSIBILITIES

Candida albicans

Rotavirus

Streptococcus mutans

Listeria monocytogenes Parvovirus

Celiac and colitis

Cystic fibrosis

Staphylococcal enterotoxin BAs a tool in proteomics


47/52


Terry N. Dyck President, CEO

Sharad Mistry Chief Financial Officer

John Mason Chief of Research

David Mason Chief of Operations

MANAGEMENT TEAM


48/52


Dr. Stu Richie Canadian Poultry Consultants Ltd.

Roger Upton, President Ironwood Clay Company

Ian Cooke Facilities Engineer

Ameann DeJohn Ameann Solutions, CA

Bob Jones, Principle Scientia Advisors

John Henderson, President Brain Box Communications

CONSULTANTS


49/52


Ron Bayne President of GloBayne

Dr. John Webb Director of Science, Maple Leaf Foods

Ken Boshcoff Governmental Affairs

Dr. Frank Mauro Periodontist

Dr. Sheetal Sapra Dermatology

Dr. Keith Ly Dermatology

Dr. Jeanette Jacknin Dermatology

ADVISORY BOARD


50/52


LEGAL TEAM

Michael Strickland, corporate affairs Bust & Partners, Thunder Bay, ON

Jay Lefton, securities law Ogilvy Renault, Toronto

Stephen Burri, Intellectual Property Miller Thomson, Vancouver

John Cameron, BDO Dunwoody Auditors, Thunder Bay


51/52


Terry N. Dyck, President and CEO

Kevin Nephin

Dr. Brian Scott

Rashid Ahmed

Sharad Mistry

BOARD OF DIRECTORS


52/52

A New Beginning

Boosting the Immune System,

Prevention is the Cure.

QUESTIONS AND ANSWERS

igy_presentation jan 2010 nml wpg

Documents